Coverage of the latest and most clinically impactful data from the American College of Cardiology's 71st Scientific Sessions. Taking place in-person in Washington D.C. with a virtual experience available online, ACC.22 is scheduled to be held from April 2-4 and feature more than 3000 abstracts and more than 80 live streaming sessions. Coverage of the event will include articles on late-breaking data, video interviews with leading experts, and more.
April 06, 2022
Data from POISE-3 presented at ACC.22 detail the effects of tranexamic acid on reducing the risk of major bleeding in patients undergoing noncardiac surgery.
April 06, 2022
Muthiah Vaduganathan, MD, MPH, discusses a study he took part in assessing the cost-effectiveness of sacubitril/valsartan among patients with an ejection fraction below normal.
April 06, 2022
Data from a phase 2b trial of bentracimab presented by Deepak Bhatt, MD, MPH, at ACC.22 demonstrates it the ability for reversing antiplatelet effects in an older population.
April 06, 2022
Deepak Bhatt, MD, MPH, discusses the results of a prespecified analysis of the COMPLETE detailing a complete revascularization approach to PCI in STEMI resulted in less angina burden than a culprit-lesion-only approach at 3 years.
April 05, 2022
Don't Miss a Beat hosts Drs. Vaduganathan and Greene provide insight into the results of trials from ACC.22 late-breaking sessions they highlighted in the preview episode they recorded ahead of the American College of Cardiology's 71st Annual Scientific Session.
April 04, 2022
Viet Le, PA-C, provides perspective on an ACC.22 study examining long-term risk of MACE based on alcohol consumption and whether or not the patient had a history of statin use.
April 04, 2022
Data from the DIAMOND trial suggests use of patiromer could help patients maintain optimized RAASi therapy, even if they were experiencing or had a history of hyperkalemia.
April 04, 2022
Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.
April 04, 2022
A large-scale analysis of data from a pair of RCTs and a nonrandomized registry provide insight into the risk of valve deterioration seen with TAVR vs SAVR and to what extent this might influence risk of mortality.